SITC 2020 - 35th Annual Meeting of the Society for Immunotherapy of Cancer (Virtual Meeting)
Nov 09 - Nov 14, 2020 | National HarborMDUS
LARVOL is not affiliated with 35th Annual Meeting of the Society for Immunotherapy of Cancer (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 439 abstracts linked to Trials
[VIRTUAL] Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
[VIRTUAL] First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
[VIRTUAL] An Open-label, multicenter, Phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts
[VIRTUAL] AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
[VIRTUAL] Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist
[VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors
[VIRTUAL] Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma
[VIRTUAL] Scientific correlatives from LCCC 1525: A Phase II Study of a Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat Metastatic Triple Negative Breast Cancer
[VIRTUAL] Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
[VIRTUAL] Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors
[VIRTUAL] Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor
[VIRTUAL] Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)
[VIRTUAL] The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer
[VIRTUAL] Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180
[VIRTUAL] Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)